Le Congrès de la European Society for Medical Oncology est le rendez-vous incontournable pour tous les chercheurs européens dans le domaine du cancer. Cette année, il aura lieu à l’IFEMA Madrid, du 20 au 24 octobre 2023.
Cette année encore, Unicancer est présent à l’occasion du congrès ESMO 2023 et est fier de présenter de nombreux posters et présentations orales illustrant le dynamisme de la Recherche Unicancer.
Toutes les informations (informations pratiques, inscriptions, programme) sur le congrès sont disponibles ici.
Présentations orales
Le Groupe Médecine Personnalisée
- Etude PEVOsq : Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial, 2023, C. Coutzac1, F. Bigot2, D. Vansteene3, M. Dos Santos4, F. Ghiringhelli5, B. You6, A. Lambert7, C. Gomez-Roca8, C. Abdeddaim9, C. Neuzillet10, E. Jeannot11, E. Guerini Rocco12, G. Frige13, L. Mazzarella14, C. Dupain15, M. Kamal15, F. Legrand16, M. Jimenez17, T. Filleron18, C. Le Tourneau2
Posters
Etude AcSé Nivolumab : Anti-PD1 Efficacy in European Patients with Advanced MSI-H/MMRd Non-Colorectal Cancers, 2023, C. Tournigand1, A. Flechon2, S. Oudard3, E. Saada4, D. Pouessel5, C. Le Tourneau6, P. Augereau7, M. Beylot-Barry8, J.J. Grob9, B. Chibaudel10, J.-C. Soria11, C. Simon12, A. Lamrani-Ghaouti13, F. Legrand14, L. Gambotti15, S. Chevret16, T. André17, A. Marabelle11
Le Groupe Médecine Personnalisée
- Etude PEVOsq : Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma – subgroup analysis of the PEVOsq basket trial, 2023, O. Le Saux1, C. Borel2, F. Ghiringhelli3, F. Bigot4, D. Vansteene5, R. Chaltiel6, S. Cousin7, X. Durando8, E. Coquan9, C. Abdeddaim10, E. Jeannot11, E. Guerini Rocco12, G. Frige13, M. Francisco14, M. Halladjian14, M. Kamal15, F. Legrand16, M. Jimenez17, B. Cabarrou18, C. Le Tourneau19
- Etude PEVOsq : Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial, 2023, M. Saint-Ghislain1, C. Abdeddaim2, R. Chaltiel3, S. Cousin4, C. Gomez-Roca5, C. Borel6, F. Ghiringhelli7, D. Vansteene8, F. Bigot9, E. Jeannot10, E. Guerini Rocco11, G. Frige12, L. Mazzarella13, M. Francisco14, F. Legrand15, M. Jimenez16, M. Halladjian14, M. Kamal17, B. Cabarrou18, C. Le Tourneau1
- Etude PEVOsq : Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial, 2023, Le Tourneau1, F. Ghiringhelli2, E. Saada3, R. Chaltiel4, D. Vansteene5, X. Durando6, B. You7, C. Borel8, F. Bigot9, C. Abdeddaim10, G. Marret11, E. Jeannot12, E. Guerini Rocco13, G. Frige14, N. Servant15, C. Dupain16, M. Kamal16, F. Legrand17, M. Jimenez18, T. Filleron19
- Etude PEVOsq : Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis – subgroup analysis of the PEVOsq basket trial, 2023, E. Coquan1, C. Gomez-Roca2, A. Lambert3, B. You4, D. Vansteene5, F. Bigot6, S. Cousin7, Z. Castel Ajgal8, E. Jeannot9, E. Guerini Rocco10, G. Frige11, L. Mazzarella12, M. Francisco13, N. Servant13, M. Halladjian13, M. Kamal14, F. Legrand15, M. Jimenez16, B. Cabarrou17, C. Le Tourneau18
Le Groupe UCGI – Groupe Gastro-intestinal d’Unicancer
- Etude PRODIGE 58 – UCGI 35 – REGIRI : Cell-free DNA analysis in patients with metastatic gastroesophagial adenocarcinoma: preliminary results of the REGIRI – PRODIGE 58 ancillary study, 2023
- Etude UCGI 26 – PRODIGE 29 – NEOPAN : PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a Phase III randomised trial comparing chemotherapy with Folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC), 2023, M.P. Ducreux1, R. Desgrippes2, Y. Rinaldi3, F. Di Fiore4, R. Guimbaud5, L. Evesque6, J-B Bachet7, P. Vanelslander8, T Lecomte9, O. Capitain10, A. Parzy11, M. Bolliet12, P-L. Etienne13, J. Forestier14, F. El Hajbi15, A-L. Bignon16, V. Lebrun-Ly17, N. De Sousa Carvalho18, M. Texier19, O. Bouche20
Etude BEPCOME – MB : BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery, 2023, P. Saiag1 , S. Gourgou2 , J. Régis3 , T. Amaral4 , U. Leiter-Stoppke5 , F.C. Bidard6 , C. Garbe7 , J.J. Grob8 , T. Lacornerie9 , A. Lamrani-Ghaouti10 , D. Couch11 , M. Charissoux12